Skip to content

Study · Non-randomized trial · n = 12 · 1996

15 results

Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.

Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR

Diabetes1 Jan 1996Cited by 186 (Europe PMC)

PMID8522066 (opens in a new tab)DOI10.2337/diab.45.1.91 (opens in a new tab)PepBankPUB-08522066
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with type II diabetes, significant side effects occurred in some subjects receiving rhIGF-I.

    In plain wordsIn patients with type II diabetes, significant side effects occurred in some subjects receiving rhIGF-I.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicableSignificant side effects
    Study

    n = 12

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Significant side effects were present in some subjects, although nine subjects were able to complete at least 4.5 weeks of the protocol and six subjects completed the entire 6 weeks.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  2. 02HumanNon-randomized trialOther

    Among rhIGF-I recipients, nine completed at least 4.5 weeks and six completed the entire 6 weeks.

    In plain wordsAmong rhIGF-I recipients, nine completed at least 4.5 weeks and six completed the entire 6 weeks.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicableProtocol completion
    Study

    n = 12

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    subjects completing at least 4.5 weeks
    9 subjects
    protocol
    subjects completing the entire 6 weeks
    6 subjects
    protocol

    Source sentences

    Summary
    Significant side effects were present in some subjects, although nine subjects were able to complete at least 4.5 weeks of the protocol and six subjects completed the entire 6 weeks.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  3. 03HumanNon-randomized trialEfficacy outcome

    In obese patients with type II diabetes, rhIGF-I significantly lowered blood glucose.

    In plain wordsIn obese patients with type II diabetes, rhIGF-I lowered blood glucose.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseBlood glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous administration of rhIGF-I (100 micrograms/kg b.i.d.) significantly lowered blood glucose.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with type II diabetes, fructosamine declined from 369 to 299 mumol/l and then to 271 during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, fructosamine declined during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseFructosamine
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    fructosamine
    369 mumol/l
    pretreatment
    fructosamine
    299 mumol/l
    3 weeks of administration
    fructosamine
    271 mumol/l
    end of 5 weeks

    Source sentences

    Summary
    Fructosamine declined from 369 to 299 mumol/l by 3 weeks of administration and then declined further to 271 at the end of 5 weeks.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with type II diabetes, glycosylated hemoglobin declined from 10.4% to 8.1% during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, glycosylated hemoglobin declined from 10.4% to 8.1% during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseGlycosylated hemoglobin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    glycosylated hemoglobin
    10.4%
    pretreatment
    glycosylated hemoglobin
    8.1%
    end of therapy

    Source sentences

    Summary
    Glycosylated hemoglobin, which was 10.4% pretreatment, declined to 8.1% at the end of therapy.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with type II diabetes, mean modal-day blood glucose declined during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, mean daily blood glucose declined during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseMean 24-h blood glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    mean 24-h blood glucose
    14.71 mmol/l
    pretreatment, modal day, +/- 4.5
    mean 24-h blood glucose
    9.1 mmol/l
    end of treatment, modal day, +/- 3.21

    Source sentences

    Summary
    Mean 24-h blood glucose during a modal day was 14.71 +/- 4.5 mmol/l pretreatment and declined to 9.1 +/- 3.21 mmol/l by the end of treatment.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  7. 07HumanNon-randomized trialMechanism

    In patients with type II diabetes, modal-day insulin concentrations declined from 108.0 to 57.0 pmol/l during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, daily insulin concentrations declined during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseModal-day insulin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    mean insulin concentration
    108 pmol/l
    modal day, before treatment
    mean insulin concentration
    57 pmol/l
    modal day, after treatment

    Source sentences

    Summary
    Mean insulin concentrations declined from 108.0 to 57.0 pmol/l during the modal day measurements and from 97.2 to 72.0 pmol/l during the mixed-meal tolerance test.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  8. 08HumanNon-randomized trialMechanism

    In patients with type II diabetes, mixed-meal insulin concentrations declined from 97.2 to 72.0 pmol/l during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, insulin concentrations during a mixed-meal test declined during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseMixed-meal insulin
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    mean insulin concentration
    97.2 pmol/l
    mixed-meal tolerance test, before treatment
    mean insulin concentration
    72 pmol/l
    mixed-meal tolerance test, after treatment

    Source sentences

    Summary
    Mean insulin concentrations declined from 108.0 to 57.0 pmol/l during the modal day measurements and from 97.2 to 72.0 pmol/l during the mixed-meal tolerance test.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with type II diabetes, the insulin sensitivity index increased 3.4-fold during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, the insulin sensitivity index increased 3.4-fold during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseInsulin sensitivity index
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    insulin sensitivity index (SI) change
    3.4-fold
    FSIVGTT, during treatment

    Source sentences

    Summary
    The insulin sensitivity index (SI) calculated from a frequently sampled intravenous glucose tolerance test (FSIVGTT) after the method of Bergman et al. (Bergman RN, Finegold DT, Ader M: Assessment of insulin sensitivity in vivo. Endocr Rev 6:45-86, 1985) increased 3.4-fold.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  10. 10HumanNon-randomized trialEfficacy outcome

    In patients with type II diabetes, rhIGF-I treatment was accompanied by a 2.1% loss in body fat.

    In plain wordsIn patients with type II diabetes, rhIGF-I treatment was accompanied by a 2.1% loss in body fat.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseBody fat
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    body fat loss
    2.1%
    by dual energy x-ray absorptiometry

    Source sentences

    Summary
    Furthermore, the improvement in glycemic control was accompanied by a change in body composition with a 2.1% loss in body fat as calculated by dual energy x-ray absorptiometry without change in total body weight.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with type II diabetes, total body weight did not change during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, total body weight did not change during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeTotal body weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Furthermore, the improvement in glycemic control was accompanied by a change in body composition with a 2.1% loss in body fat as calculated by dual energy x-ray absorptiometry without change in total body weight.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  12. 12HumanNon-randomized trialPharmacokinetics

    In patients with type II diabetes, IGF-I concentrations increased during rhIGF-I treatment and remained supraphysiological.

    In plain wordsIn patients with type II diabetes, IGF-I concentrations increased during rhIGF-I treatment and remained above normal levels.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseIGF-I concentrations
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Measurements

    serum IGF-I
    206 micrograms/l
    control period
    serum IGF-I
    849 micrograms/l
    end of 6 weeks of rhIGF-I

    Source sentences

    Summary
    Supraphysiological IGF-I concentrations were maintained throughout the study, increasing from 206 micrograms/l in the control period to 849 micrograms/l at the end of 6 weeks of rhIGF-I treatment.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  13. 13HumanNon-randomized trialMechanism

    In patients with type II diabetes, IGF binding protein-2 increased significantly during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, IGF binding protein-2 increased during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseIGF binding protein-2
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    The increase in IGF-I levels was accompanied by a significant increase in IGF binding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels of IGF binding protein-1.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  14. 14HumanNon-randomized trialMechanism

    In patients with type II diabetes, IGF binding protein-3 decreased slightly during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, IGF binding protein-3 decreased slightly during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseIGF binding protein-3
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    The increase in IGF-I levels was accompanied by a significant increase in IGF binding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels of IGF binding protein-1.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.
  15. 15HumanNon-randomized trialMechanism

    In patients with type II diabetes, IGF binding protein-1 increased during rhIGF-I treatment.

    In plain wordsIn patients with type II diabetes, IGF binding protein-1 increased during rhIGF-I treatment.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseIGF binding protein-1
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Metabolic and weight
    Studied dose
    100 micrograms/kg b.i.d. · subcutaneous · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    The increase in IGF-I levels was accompanied by a significant increase in IGF binding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels of IGF binding protein-1.
    1 context sentence
    Summary · context
    Since IGFs exert insulin-like actions and increase insulin sensitivity when administered at supraphysiological doses, we determined the effect of 6 weeks of recombinant human IGF-I (rhIGF-I) administration on insulin resistance and glycemic control in obese insulin-resistant patients with type II diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.